fbpx Opioid Agonist Therapy (OAT) and lower risk of multiple causes of death | NDARC - National Drug and Alcohol Research Centre

Opioid Agonist Therapy (OAT) and lower risk of multiple causes of death

Tom Santo Jr.
Resource Type: NDARC Seminars

Tom Santo Jr presented at the NDARC Webinar Series on Thursday 8 July, 2021. 

This webinar shared findings from a systematic review that examined mortality and causes of death among people with opioid dependence.

Mortality among people with opioid dependence is much higher than that of the general population. Opioid agonist treatment (OAT), which includes methadone and buprenorphine treatment, is an effective treatment for opioid dependence. We examined mortality rates by time during and out of OAT, by cause of death, study methodology, participant characteristics, and setting.

 

About the speaker

Tom Santo Jr is a PhD Candidate at NDARC, UNSW Sydney. He completed his Master of Public Health and began working at NDARC in 2018. Tom’s research interests include prevention and treatment of both pharmaceutical and opioid use disorder (OUD). The focus of his PhD is the relationship between childhood maltreatment, mental disorders and OUD among people who use opioids.

Please note: readers and audience are encouraged to go to the presenter’s published paper for the most fulsome account of the research and its findings. Read here